Henoch-Schönlein purpura (HSP) is a small vessel vasculitis with IgA deposits in capillaries of the skin, kidneys and gastrointestinal tract, often affecting male children from 2 to 10 years.1-20 This non-thrombocytopenic purpura was first described by Johann Lukas Schönlein (1832) and Edouard Heinrich Henoch (1868),17 and the lesions predominates in lower extremities.1,5,8,11,13-15,17,18 Manifestations include palpable purpura, abdominal pain, enterorrhagia, arthritis, proteinuria, hematuria, besides disorders of heart, liver, pancreas, lungs, adrenals, and central nervous system.1-20 The incidence is 10-20 cases/100,000 in children and 0.8-5.1 cases/100,000 in adults; associated factors include drugs, infections, insect bites, malignancy and vaccines; and the pathogenesis involves the B-cells and complement activation, autoantibodies as anticardiolipin IgA with vasculitis.1-20 Infections more related to IgA vasculitis are by group A -hemolytic streptococcus, influenza, parainfluenza, respiratory syncytial virus, adenovirus, besides the Betacoronavirus and vaccines.1-20 The diagnosis is based on clinical data, and confirmed by laboratory tests; the treatment can include corticosteroids, rituximab, cyclophosphamide, azathioprine, and mycophenolate mofetil.1-8,9-20 Antiplatelet or anticoagulant therapies may be indicated in COVID-19 associated severe vasculitis.2 Currently, there is a growing worldwide interest on the occurrence of HSP in individuals of all age groups, who had COVID-19 infection or were vaccinated against the SARS-CoV-2 infection.1-16,18-20 Vascular endothelial injury and organ vasculitis observed in COVID-19 infection may be due to direct infection of endothelial cells, or a consequence of the inflammatory reaction caused by the infection.1 Herein are commented more recent case reports, case series, and literature reviews about this issues. HSP and COVID-19 infection or vaccination.
